• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

术前血清血管内皮生长因子可预测结直肠癌的分期。

Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer.

作者信息

Kumar H, Heer K, Lee P W, Duthie G S, MacDonald A W, Greenman J, Kerin M J, Monson J R

机构信息

University of Hull Academic Surgical Unit, Castle Hill Hospital, Cottingham, United Kingdom.

出版信息

Clin Cancer Res. 1998 May;4(5):1279-85.

PMID:9607588
Abstract

Neovascularization has been shown to be essential for the growth of solid tumors. Vascular endothelial growth factor (VEGF) is one of the most important mediators of angiogenesis. This study was conducted to determine the significance of this cytokine as a tumor marker for staging colorectal cancer. Preoperative serum VEGF was measured in 108 colorectal cancer patients and in 136 normal healthy controls. The results of this study showed a significant difference between the four T classes, Union International Contre Cancer (UICC) stages, and Dukes' stages. In comparison to serum levels in controls (median, 173.8 pg/ml), VEGF levels were significantly elevated in T2 (P = 0.003), T3, and T4 (P < 0.0005); UICC I (P = 0.001), UICC II, UICC III, and UICC IV (P < 0.0005); and Dukes' A (P = 0.001), Dukes' B, and Dukes' C (P < 0.0005). Serum VEGF showed a significant elevation over control in node-negative (P < 0.0005) and in node-positive colorectal cancer (P < 0.0005) patients. Node-positive cancer had a significant elevation of serum VEGF compared to node-negative cancer (P = 0.008). This study reveals that preoperative serum VEGF can detect all but very early colorectal cancer i.e., T1 (P = 0.06).

摘要

新血管生成已被证明对实体肿瘤的生长至关重要。血管内皮生长因子(VEGF)是血管生成最重要的介质之一。本研究旨在确定这种细胞因子作为结直肠癌分期肿瘤标志物的意义。对108例结直肠癌患者和136例正常健康对照者术前血清VEGF进行了检测。本研究结果显示,在四个T分期、国际抗癌联盟(UICC)分期和Dukes分期之间存在显著差异。与对照组血清水平(中位数,173.8 pg/ml)相比,T2期(P = 0.003)、T3期和T4期(P < 0.0005);UICC I期(P = 0.001)、UICC II期、UICC III期和UICC IV期(P < 0.0005);以及Dukes A期(P = 0.001)、Dukes B期和Dukes C期(P < 0.0005)的VEGF水平显著升高。血清VEGF在无淋巴结转移(P < 0.0005)和有淋巴结转移的结直肠癌患者(P < 0.0005)中均显著高于对照组。有淋巴结转移的癌症患者血清VEGF水平显著高于无淋巴结转移的癌症患者(P = 0.008)。本研究表明,术前血清VEGF除了极早期结直肠癌(即T1期,P = 0.06)外,能检测出所有结直肠癌。

相似文献

1
Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer.术前血清血管内皮生长因子可预测结直肠癌的分期。
Clin Cancer Res. 1998 May;4(5):1279-85.
2
Circulating vascular endothelial growth factor in patients with colorectal cancer.结直肠癌患者循环血管内皮生长因子
Am J Gastroenterol. 1998 Feb;93(2):249-52. doi: 10.1111/j.1572-0241.1998.00249.x.
3
Correlation of plasma level and immunohistochemical expression of vascular endothelial growth factor in patients with advanced colorectal cancer.晚期结直肠癌患者血浆血管内皮生长因子水平与免疫组化表达的相关性
Anticancer Res. 2002 Sep-Oct;22(5):2957-63.
4
Clinical significance of serum vascular endothelial growth factor in colorectal cancer patients: correlation with clinicopathological factors and tumor markers.血清血管内皮生长因子在结直肠癌患者中的临床意义:与临床病理因素及肿瘤标志物的相关性
Oncol Rep. 2000 Mar-Apr;7(2):333-8.
5
Kinetics of postoperative serum vascular endothelial growth factor (VEGF)--can it be used to predict curative resections in colorectal cancer?术后血清血管内皮生长因子(VEGF)的动力学——它能否用于预测结直肠癌的根治性切除?
Anticancer Res. 2002 Nov-Dec;22(6B):3717-22.
6
Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. The Danish RANX05 Colorectal Cancer Study Group.原发性结直肠癌患者可溶性血管内皮生长因子水平。丹麦RANX05结直肠癌研究组。
Eur J Surg Oncol. 2000 Nov;26(7):657-62. doi: 10.1053/ejso.2000.0977.
7
Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer.术前血清血管内皮生长因子可用于筛选接受结直肠癌根治性切除术后辅助治疗的患者。
Br J Cancer. 2000 Dec;83(11):1425-31. doi: 10.1054/bjoc.2000.1508.
8
Preoperative plasma vascular endothelial growth factor but not nitrite is a useful complementary tumor marker in patients with colorectal cancer.术前血浆血管内皮生长因子而非亚硝酸盐是结直肠癌患者有用的辅助肿瘤标志物。
Dis Colon Rectum. 2006 Jun;49(6):883-94. doi: 10.1007/s10350-006-0528-z.
9
Elevated IL-8 levels in the drainage vein of resectable Dukes' C colorectal cancer indicate high risk for developing hepatic metastasis.可切除的Dukes' C期结肠癌引流静脉中白细胞介素-8水平升高表明发生肝转移的风险较高。
Oncol Rep. 2002 Jan-Feb;9(1):159-65.
10
Relationship between plasma levels of vascular endothelial growth factor and serum levels of interleukin-12 in patients with colorectal cancer.结直肠癌患者血浆血管内皮生长因子水平与血清白细胞介素-12水平的关系。
Anticancer Res. 2000 Nov-Dec;20(6A):4097-102.

引用本文的文献

1
Blocking Tumoral Angiogenesis VEGF/VEGFR Pathway: Bevacizumab-20 Years of Therapeutic Success and Controversy.阻断肿瘤血管生成VEGF/VEGFR通路:贝伐单抗——20年的治疗成功与争议
Cancers (Basel). 2025 Mar 27;17(7):1126. doi: 10.3390/cancers17071126.
2
Bevacizumab-Based Therapies in Malignant Tumors-Real-World Data on Effectiveness, Safety, and Cost.基于贝伐单抗的恶性肿瘤治疗——有效性、安全性和成本的真实世界数据
Cancers (Basel). 2024 Jul 19;16(14):2590. doi: 10.3390/cancers16142590.
3
Prognostic Values of Tissue and Serum Angiogenic Growth Factors Depend on the Phenotypic Subtypes of Colorectal Cancer.
组织和血清血管生成生长因子的预后价值取决于结直肠癌的表型亚型。
Cancers (Basel). 2023 Jul 29;15(15):3871. doi: 10.3390/cancers15153871.
4
Serum vascular endothelial growth factor in dogs with various proliferative diseases.各种增殖性疾病犬血清血管内皮生长因子。
J Vet Med Sci. 2022 May 25;84(5):720-725. doi: 10.1292/jvms.21-0509. Epub 2022 Apr 4.
5
The Prognostic Value of Circulating VEGF-A Level in Patients With Hepatocellular Cancer.循环 VEGF-A 水平对肝癌患者的预后价值。
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820971677. doi: 10.1177/1533033820971677.
6
Sarcoma treatment in the era of molecular medicine.肉瘤的分子医学治疗时代。
EMBO Mol Med. 2020 Nov 6;12(11):e11131. doi: 10.15252/emmm.201911131. Epub 2020 Oct 13.
7
Circulating cytokines and outcome in metastatic colorectal cancer patients treated with regorafenib.接受瑞戈非尼治疗的转移性结直肠癌患者的循环细胞因子与预后
World J Gastrointest Oncol. 2020 Mar 15;12(3):301-310. doi: 10.4251/wjgo.v12.i3.301.
8
Unexpected and durable response with regorafenib in a metastatic colorectal cancer patient without KDR mutation: A case report.瑞戈非尼对一名无KDR突变的转移性结直肠癌患者产生意外且持久的反应:一例病例报告。
Medicine (Baltimore). 2018 Jun;97(25):e11178. doi: 10.1097/MD.0000000000011178.
9
Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer.血清血管内皮生长因子-A(VEGF-A)和趋化因子配体5(CCL5)水平作为转移性结直肠癌患者中瑞戈非尼疗效和毒性的候选生物标志物。
Oncotarget. 2016 Jun 7;7(23):34811-23. doi: 10.18632/oncotarget.9187.
10
Increased pre-surgical numbers of endothelial progenitor cells and circulating endothelial cells in colorectal cancer fail to predict outcome.结直肠癌患者术前内皮祖细胞和循环内皮细胞数量增加并不能预测预后。
Int J Colorectal Dis. 2015 Mar;30(3):315-21. doi: 10.1007/s00384-014-2116-3. Epub 2015 Jan 20.